<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en-GB">
	<id>https://en.longevitywiki.org/wiki/Inflammaging_protein_markers/history?feed=atom</id>
	<title>Inflammaging protein markers - Revision history</title>
	<link rel="self" type="application/atom+xml" href="https://en.longevitywiki.org/wiki/Inflammaging_protein_markers/history?feed=atom"/>
	<link rel="alternate" type="text/html" href="https://en.longevitywiki.org/wiki/Inflammaging_protein_markers/history"/>
	<updated>2026-04-05T03:52:21Z</updated>
	<subtitle>Revision history for this page on the wiki</subtitle>
	<generator>MediaWiki 1.41.0</generator>
	<entry>
		<id>https://en.longevitywiki.org/index.php?title=Inflammaging_protein_markers&amp;diff=3309&amp;oldid=prev</id>
		<title>Dmitry Dzhagarov at 19:58, 16 July 2024</title>
		<link rel="alternate" type="text/html" href="https://en.longevitywiki.org/index.php?title=Inflammaging_protein_markers&amp;diff=3309&amp;oldid=prev"/>
		<updated>2024-07-16T19:58:25Z</updated>

		<summary type="html">&lt;p&gt;&lt;/p&gt;
&lt;table style=&quot;background-color: #fff; color: #202122;&quot; data-mw=&quot;interface&quot;&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;tr class=&quot;diff-title&quot; lang=&quot;en-GB&quot;&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;← Older revision&lt;/td&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;Revision as of 19:58, 16 July 2024&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l1&quot;&gt;Line 1:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 1:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;Some inflammatory protein markers, especially &amp;#039;&amp;#039;&amp;#039;CXCL9&amp;#039;&amp;#039;&amp;#039; (Chemokine (C-X-C motif) ligand 9) and &amp;#039;&amp;#039;&amp;#039;OPG&amp;#039;&amp;#039;&amp;#039; (Osteoprotegerin), could distinguish long-living and elderly correctly which could be used to predict lifespan combined with other anti-aging markers.&amp;lt;ref&amp;gt;Jie Liu, Qifu Zhu, Dan Zhang, Qihui Yu, Xin Zheng, Shuihong Yao, and Xinhua Wang (2024) Exploring the expression profiles of serum inflammatory proteins and potential anti-aging targets in Chinese long-living people. Rejuvenation Research.  https://doi.org/10.1089/rej.2024.0038&amp;lt;/ref&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;Some inflammatory protein markers, especially &amp;#039;&amp;#039;&amp;#039;CXCL9&amp;#039;&amp;#039;&amp;#039; (Chemokine (C-X-C motif) ligand 9) and &amp;#039;&amp;#039;&amp;#039;OPG&amp;#039;&amp;#039;&amp;#039; (Osteoprotegerin), could distinguish long-living and elderly correctly which could be used to predict lifespan combined with other anti-aging markers.&amp;lt;ref&amp;gt;Jie Liu, Qifu Zhu, Dan Zhang, Qihui Yu, Xin Zheng, Shuihong Yao, and Xinhua Wang (2024) Exploring the expression profiles of serum inflammatory proteins and potential anti-aging targets in Chinese long-living people. Rejuvenation Research.  https://doi.org/10.1089/rej.2024.0038&amp;lt;/ref&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;Chemokine (C-X-C motif) ligand 9 (CXCL9) is a small cytokine belonging to the CXC chemokine family that is also known as monokine induced by gamma interferon (MIG). The CXCL9 is one of the chemokine which plays role to induce chemotaxis, promote differentiation and multiplication of leukocytes, and cause tissue extravasation. Among the multiple pro-inflammatory proteins identified, the CXC-motif chemokine ligand 9 (CXCL9) had the strongest correlation with inflammation. Elevated CXCL9 was associated with frailty and is a major predictor of morbidity and mortality,&amp;lt;ref&amp;gt;Kojima, G., Iliffe, S., &amp;amp; Walters, K. (2018). Frailty index as a predictor of mortality: a systematic review and meta-analysis. Age and ageing, 47(2), 193-200. PMID: 29040347 DOI: 10.1093/ageing/afx162&amp;lt;/ref&amp;gt; along with falls and fractures in older adults Greater serum levels of CXCL9 were significantly associated with a decline in chair stands and increased mortality.&amp;lt;ref&amp;gt;Seo, D. H., Corr, M., Patel, S., Lui, L. Y., Cauley, J. A., Evans, D., ... &amp;amp; Lane, N. E. (2024). Chemokine CXCL9, a marker of inflammaging, is associated with changes of muscle strength and mortality in older men. Osteoporosis International, 1-8. PMID: 38965121 DOI: 10.1007/s00198-024-07160-y&amp;lt;/ref&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;&#039;&#039;&#039;&lt;/ins&gt;Chemokine (C-X-C motif) ligand 9 (CXCL9)&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;&#039;&#039;&#039; &lt;/ins&gt;is a small cytokine belonging to the CXC chemokine family that is also known as monokine induced by gamma interferon (MIG). The CXCL9 is one of the chemokine which plays role to induce chemotaxis, promote differentiation and multiplication of leukocytes, and cause tissue extravasation. Among the multiple pro-inflammatory proteins identified, the CXC-motif chemokine ligand 9 (CXCL9) had the strongest correlation with inflammation. Elevated CXCL9 was associated with &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;[[&lt;/ins&gt;frailty&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;]] &lt;/ins&gt;and is a major predictor of morbidity and mortality,&amp;lt;ref&amp;gt;Kojima, G., Iliffe, S., &amp;amp; Walters, K. (2018). Frailty index as a predictor of mortality: a systematic review and meta-analysis. Age and ageing, 47(2), 193-200. PMID: 29040347 DOI: 10.1093/ageing/afx162&amp;lt;/ref&amp;gt; along with falls and fractures in older adults Greater serum levels of CXCL9 were significantly associated with a decline in chair stands and increased mortality.&amp;lt;ref&amp;gt;Seo, D. H., Corr, M., Patel, S., Lui, L. Y., Cauley, J. A., Evans, D., ... &amp;amp; Lane, N. E. (2024). Chemokine CXCL9, a marker of inflammaging, is associated with changes of muscle strength and mortality in older men. Osteoporosis International, 1-8. PMID: 38965121 DOI: 10.1007/s00198-024-07160-y&amp;lt;/ref&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;Osteoprotegerin (OPG), also known as osteoclastogenesis inhibitory factor (OCIF) or tumour necrosis factor receptor superfamily member 11B (TNFRSF11B), is a cytokine receptor of the tumour necrosis factor (TNF) receptor superfamily encoded by the TNFRSF11B gene. OPG has been proposed as a modulator of inflammation including the regulation of lymphocytes and apoptosis and as a participant in the pathogenesis of atherosclerosis in cardiovascular disease.&amp;lt;ref&amp;gt;Zhu, Z., Guo, D., Zhang, K., Yang, P., Jia, Y., Shi, M., ... &amp;amp; He, J. (2023). Osteoprotegerin and ischemic stroke prognosis: a prospective multicenter study and mendelian randomization analysis. Stroke, 54(2), 509-517. PMID: 36511149 DOI: 10.1161/STROKEAHA.122.040800&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;Pang L, Lin H, Wei X, Wei W, Lan Y (2024) Prognostic effect of osteoprotegerin in patients with ischemic stroke: A systematic review and meta-analysis. PLoS ONE 19(5): e0303832.  PMID: 38820283 PMC11142426 [https://doi.org/10.1371/journal.pone.0303832 DOI: 10.1371/journal.pone.0303832]&amp;lt;/ref&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;&#039;&#039;&#039;&lt;/ins&gt;Osteoprotegerin (OPG)&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;&#039;&#039;&#039;&lt;/ins&gt;, also known as osteoclastogenesis inhibitory factor (OCIF) or tumour necrosis factor receptor superfamily member 11B (TNFRSF11B), is a cytokine receptor of the tumour necrosis factor (TNF) receptor superfamily encoded by the TNFRSF11B gene. OPG has been proposed as a modulator of inflammation including the regulation of lymphocytes and apoptosis and as a participant in the pathogenesis of atherosclerosis in cardiovascular disease.&amp;lt;ref&amp;gt;Zhu, Z., Guo, D., Zhang, K., Yang, P., Jia, Y., Shi, M., ... &amp;amp; He, J. (2023). Osteoprotegerin and ischemic stroke prognosis: a prospective multicenter study and mendelian randomization analysis. Stroke, 54(2), 509-517. PMID: 36511149 DOI: 10.1161/STROKEAHA.122.040800&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;Pang L, Lin H, Wei X, Wei W, Lan Y (2024) Prognostic effect of osteoprotegerin in patients with ischemic stroke: A systematic review and meta-analysis. PLoS ONE 19(5): e0303832.  PMID: 38820283 PMC11142426 [https://doi.org/10.1371/journal.pone.0303832 DOI: 10.1371/journal.pone.0303832]&amp;lt;/ref&amp;gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;=== References ===&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;=== References ===&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>Dmitry Dzhagarov</name></author>
	</entry>
	<entry>
		<id>https://en.longevitywiki.org/index.php?title=Inflammaging_protein_markers&amp;diff=3308&amp;oldid=prev</id>
		<title>Dmitry Dzhagarov: Created page with &quot;Some inflammatory protein markers, especially &#039;&#039;&#039;CXCL9&#039;&#039;&#039; (Chemokine (C-X-C motif) ligand 9) and &#039;&#039;&#039;OPG&#039;&#039;&#039; (Osteoprotegerin), could distinguish long-living and elderly correctly which could be used to predict lifespan combined with other anti-aging markers.&lt;ref&gt;Jie Liu, Qifu Zhu, Dan Zhang, Qihui Yu, Xin Zheng, Shuihong Yao, and Xinhua Wang (2024) Exploring the expression profiles of serum inflammatory proteins and potential anti-aging targets in Chinese long-living peop...&quot;</title>
		<link rel="alternate" type="text/html" href="https://en.longevitywiki.org/index.php?title=Inflammaging_protein_markers&amp;diff=3308&amp;oldid=prev"/>
		<updated>2024-07-16T19:53:15Z</updated>

		<summary type="html">&lt;p&gt;Created page with &amp;quot;Some inflammatory protein markers, especially &amp;#039;&amp;#039;&amp;#039;CXCL9&amp;#039;&amp;#039;&amp;#039; (Chemokine (C-X-C motif) ligand 9) and &amp;#039;&amp;#039;&amp;#039;OPG&amp;#039;&amp;#039;&amp;#039; (Osteoprotegerin), could distinguish long-living and elderly correctly which could be used to predict lifespan combined with other anti-aging markers.&amp;lt;ref&amp;gt;Jie Liu, Qifu Zhu, Dan Zhang, Qihui Yu, Xin Zheng, Shuihong Yao, and Xinhua Wang (2024) Exploring the expression profiles of serum inflammatory proteins and potential anti-aging targets in Chinese long-living peop...&amp;quot;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;New page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;Some inflammatory protein markers, especially &amp;#039;&amp;#039;&amp;#039;CXCL9&amp;#039;&amp;#039;&amp;#039; (Chemokine (C-X-C motif) ligand 9) and &amp;#039;&amp;#039;&amp;#039;OPG&amp;#039;&amp;#039;&amp;#039; (Osteoprotegerin), could distinguish long-living and elderly correctly which could be used to predict lifespan combined with other anti-aging markers.&amp;lt;ref&amp;gt;Jie Liu, Qifu Zhu, Dan Zhang, Qihui Yu, Xin Zheng, Shuihong Yao, and Xinhua Wang (2024) Exploring the expression profiles of serum inflammatory proteins and potential anti-aging targets in Chinese long-living people. Rejuvenation Research.  https://doi.org/10.1089/rej.2024.0038&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Chemokine (C-X-C motif) ligand 9 (CXCL9) is a small cytokine belonging to the CXC chemokine family that is also known as monokine induced by gamma interferon (MIG). The CXCL9 is one of the chemokine which plays role to induce chemotaxis, promote differentiation and multiplication of leukocytes, and cause tissue extravasation. Among the multiple pro-inflammatory proteins identified, the CXC-motif chemokine ligand 9 (CXCL9) had the strongest correlation with inflammation. Elevated CXCL9 was associated with frailty and is a major predictor of morbidity and mortality,&amp;lt;ref&amp;gt;Kojima, G., Iliffe, S., &amp;amp; Walters, K. (2018). Frailty index as a predictor of mortality: a systematic review and meta-analysis. Age and ageing, 47(2), 193-200. PMID: 29040347 DOI: 10.1093/ageing/afx162&amp;lt;/ref&amp;gt; along with falls and fractures in older adults Greater serum levels of CXCL9 were significantly associated with a decline in chair stands and increased mortality.&amp;lt;ref&amp;gt;Seo, D. H., Corr, M., Patel, S., Lui, L. Y., Cauley, J. A., Evans, D., ... &amp;amp; Lane, N. E. (2024). Chemokine CXCL9, a marker of inflammaging, is associated with changes of muscle strength and mortality in older men. Osteoporosis International, 1-8. PMID: 38965121 DOI: 10.1007/s00198-024-07160-y&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
Osteoprotegerin (OPG), also known as osteoclastogenesis inhibitory factor (OCIF) or tumour necrosis factor receptor superfamily member 11B (TNFRSF11B), is a cytokine receptor of the tumour necrosis factor (TNF) receptor superfamily encoded by the TNFRSF11B gene. OPG has been proposed as a modulator of inflammation including the regulation of lymphocytes and apoptosis and as a participant in the pathogenesis of atherosclerosis in cardiovascular disease.&amp;lt;ref&amp;gt;Zhu, Z., Guo, D., Zhang, K., Yang, P., Jia, Y., Shi, M., ... &amp;amp; He, J. (2023). Osteoprotegerin and ischemic stroke prognosis: a prospective multicenter study and mendelian randomization analysis. Stroke, 54(2), 509-517. PMID: 36511149 DOI: 10.1161/STROKEAHA.122.040800&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;Pang L, Lin H, Wei X, Wei W, Lan Y (2024) Prognostic effect of osteoprotegerin in patients with ischemic stroke: A systematic review and meta-analysis. PLoS ONE 19(5): e0303832.  PMID: 38820283 PMC11142426 [https://doi.org/10.1371/journal.pone.0303832 DOI: 10.1371/journal.pone.0303832]&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
=== References ===&lt;br /&gt;
&amp;lt;references /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[Category:Aging pathways and hallmarks]]&lt;br /&gt;
[[Category:Main list]]&lt;br /&gt;
[[Category:Stub]]&lt;/div&gt;</summary>
		<author><name>Dmitry Dzhagarov</name></author>
	</entry>
</feed>